Veeva delivered 16% and 13% revenue and adjusted EPS growth, respectively, during first-quarter fiscal 2027. Both figures landed ahead of guidance. Full-year guidance for revenue and EPS was raised by a low single digit. Shares were down 5% afterhours.
Veeva continues to introduce new applications in areas such as safety and clinical operations to service unmet needs, which support our double-digit growth assumptions.
Bears
Moving its CRM from Salesforce’s platform to its Vault Platform could raise concerns for customers and lower its retention rate.
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company’s best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.